BCR and chronic myelogenous leukemia, BCR-ABL1 positive: This is in contrast to the highly efficient effect of dasatinib in BCR-ABL-driven diseases such as chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), characterized by the constitutively active tyrosine kinase, BCR-ABL [25].